Mara Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. Aspinall is Co-Founder and Managing Director of BlueStone Venture Partners.  Aspinall also heads the Health Catalysts Group publishing the popular Health Catalysts Diagnostics Year in Review. Aspinall is an advisor to The Rockefeller Foundation on COVID diagnostics.

Aspinall is passionate about education on diagnostics, genomics, and personalized medicine. To that end, Mara co-founded the School of Biomedical Diagnostics at Arizona State University, the first school dedicated to Diagnostics as an independent discipline.

Aspinall served as President and CEO of Ventana Medical Systems, now Roche Tissue Diagnostics, a $1 billion division of the Roche Group. Previously, she was President of Genzyme Genetics and Genzyme Pharmaceuticals.  Deeply committed to expanding learning, Aspinall was an active member of the US Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in the Obama and Bush administrations. Aspinall is also certified in Cybersecurity Oversight from Carnegie Mellon University.

Mara was named Arizona Biosciences Leader of the Year by the Arizona Bio Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE and one of Women Inc.’s Most Influential Corporate Board Directors. Ms. Aspinall holds an MBA from Harvard Business School and a BA from Tufts University.  She is a member of the Board of Directors of several publicly traded companies including Abcam plc, Allscripts, Castle Biosciences, DA32, OraSure, and Blue Cross Blue Shield Arizona. She also is a Board Member for Pyx Health and is a Board Observer for GT Medical Technologies.

Mara Aspinall

Managing Director